Attention-deficit/Hyperactivity Disorder
Conditions
Sponsors
SHIONOGI & CO., LTD.
Shire Development LLC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient aged 6 years or older to less than 18 years at the time of signing the informed consent form. 2) Patient meets the DSM-IV-TR criteria for a primary diagnosis of ADHD (predominantly inattentive type [314.00], predominantly hyperactive-impulsive type [314.01], and combined type [314.01]). And et al.
Exclusion criteria
Exclusion criteria: 1) Patient has complications such as serious hepatic disorder, renal disorder, heart disease, lung disease, hematological disease, and metabolic disease. 2) Patient has psychiatric disease such as schizophrenia, bipolar disorder, and pervasive developmental disorder. 3) Patient has personality disorder or mental retardation. 4) Patient is orthostatic hypotensive or hypertensive. 5) Patient had a documented allergy, hypersensitivity or intolerance to guanfacine hydrocholoride. 6) Patient considered a suicide risk. And et al.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of S-877503 in the treatment of Attention-deficit/hyperactivity Disorder | — |
Contacts
Public ContactContact for Clinical Trial Information
Takeda Pharmaceutical Company Limited
Outcome results
None listed